Long-term survival of a patient with relapsing triple-negative breast cancer stage IIB under surgical treatment and Viscum album extracts – A case report

10519 Objective. Triple-negative breast cancer is defined as a subtype of invasive breast cancer which lacks estrogen and progesterone receptor expression as well as HER2/neu expression and is highly similar to the basal-like subtype defined by gene expression profiling. Method. 1,143 patients treated at MD Anderson Cancer Center in neoadjuvant trials were included in a retrospective comparative analysis between triple-negative tumors and non-triple-negative tumors for response to neoadjuvant chemotherapy as well as long- term survival. Results. 827/1,143 (72%) patients had received taxanes, either as a single-agent (n=60) or in combination with anthracycline (n=767), whereas the remainder patients received an anthracycline-only chemotherapy. Overall 258/1,143 (23%) tumors were triple- negative. Complete pathological response (pCR) was achieved in 63/257 (25%) patients with triple-negative tumors compared to 99/888 (11%) in patients with non-triple-negative tumors (odds ratio [OR] 1.14, 95%CI: 1.09–1.20, p=.0082). Triple-negative status correlated significantly with high nuclear grade (p<.0001), whereas no significant correlation with any established clinicopathologic parameter was observed. However, 5-year overall survival (5yrOS) was 66% in the triple-negative group compared to 83% in the non-triple-negative control group (OR 2.1, 95%CI: 1.6–2.8, p<.0001). In multivariate analyses, triple-negative status (hazard ratio [HR] 2.0, 95%CI: 1.4–2.8, p<.0001), high nuclear grade, increased tumor size (HR 1.5, 95%CI: 1.3–1.8, p<.0001), positive nodal status (HR 1.4, 95%CI: 1.2–1.7, p=.0002) and high nuclear grade (HR 1.7, 95%CI: 1.1- 2.4, p=.0089) were significantly associated with decreased 5yrOS. When survival was analyzed according to both response rate and triple negative status, achievement of pCR was a stronger predictor of survival compared to triple-negative status. Conclusion. Triple- negative expression status among patients with breast cancer constitutes an independent unfavorable prognostic factor with regards to overall survival unless achieving pCR after neoadjuvant chemotherapy. No significant financial relationships to disclose.

Download Full-text

The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients

PLoS ONE ◽

10.1371/journal.pone.0143061 ◽

2015 ◽

Vol 10 (11) ◽

pp. e0143061 ◽

Cited By ~ 39

Author(s):

Weijuan Jia ◽

Jiannan Wu ◽

Haixia Jia ◽

Yaping Yang ◽

Xiaolan Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Blood Neutrophil ◽

Breast Cancer Patients ◽

Term Survival ◽

Peripheral Blood Neutrophil ◽

Lymphocyte To Monocyte Ratio

Download Full-text

Carboplatin (C) and Paclitaxel (P) Combination (Cp) in Triple-Negative Metastatic Breast Cancer (Tnmbc) Treatment: Long-Term Survival

Annals of Oncology ◽

10.1093/annonc/mdu329.38 ◽

2014 ◽

Vol 25 ◽

pp. iv128

Author(s):

A. Storozhakova ◽

L. Vladimirova ◽

Y. Prgedetsky ◽

I. Popova ◽

N.A. Abramova ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Triple Negative ◽

Metastatic Breast ◽

Term Survival ◽

Long Term Survival

Download Full-text

Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report

Immunotherapy ◽

10.2217/imt.15.48 ◽

2015 ◽

Vol 7 (8) ◽

pp. 855-860 ◽

Cited By ~ 12

Author(s):

Volker Schirrmacher ◽

Wilfried Stücker ◽

Maria Lulei ◽

Akos-Sigmund Bihari ◽

Tobias Sprenger

Keyword(s):

Breast Cancer ◽

Case Report ◽

Cancer Patient ◽

Liver Metastases ◽

Breast Cancer Patient ◽

Term Survival ◽

Long Term Survival

Download Full-text

Efficacy and safety of intensified platinum-based neoadjuvant chemotherapy in locally advanced triple-negative breast cancer: Preliminary results of non-randomized phase II study.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.e12116 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. e12116-e12116 ◽

Cited By ~ 1

Author(s):

Elena Glazkova ◽

Mona Frolova ◽

Marina Stenina ◽

Ekaterina Ignatova ◽

Alexey Rumyantsev ◽

...

Keyword(s):

Breast Cancer ◽

Surgical Treatment ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Brca1 Mutation ◽

Locally Advanced ◽

Common Mutation ◽

Term Survival

e12116 Background: patients with locally-advanced triple negative breast cancer (TNBC) have dismal prognosis with current standard of care therapy. Pathologic complete response (pCR) is the most important prognostic factor for long-term survival of these patients. Methods: this was non-randomized prospective single-center phase II study. Key inclusion criteria were histologically verified locally advanced TNBC, non-eligibility for primary surgical treatment (ie, TNM stage Т2-4N 2-3M0) and no evidence of metastatic disease. Patients were treated with 8 cycles of neoadjuvant doxorubicine, paclitaxel and cisplatin chemotherapy (ATP; doxorubicine 40 mg/m2 day 1, paclitaxel 160 mg/m2 day 1 and cisplatin 50 mg/m2 day 1 every two weeks) with G-CSF support (filgrastim 5 mcg/kg day 2-6). After 8 cycles of chemotherapy patients were referred for surgical treatment; adjuvant radiation therapy was prescribed to all patients. Primary end point was pCR assessed in modified intention-to-treat population (ie, in patients who underwent surgical treatment). Key secondary endpoints were disease-free survival (DFS) and pCR rate according to BRCA status. Results: we enrolled 80 patients, 79 (98.7%) of them underwent surgical treatment and were included in the analysis. Median age was 46 years (25-68), 22 (27.1%) patients had BRCA1 mutations, 5382insC was the most common mutation (17 [77.2%] of patients); 1 (1.2%) patient had CHEK2 mutation. pCR was achieved in 51 (64.5%) patients. In with BRCA1-mutation carriers pCR rate was 61.9%, in patients with 5382insC – 81.2%. 2-year DFS was 77.3%; 2-year overall survival was 91.0% . Most common grade 3-4 adverse events were anemia (29.3%), neutropenia (17.8%), neuropathy (4.9%), stomatitis (3.7%) and thrombocytopenia (1.8%). Conclusions: the ATP regimen was effective in treatment of locally-advanced TNBC, especially in patients with founder 5382insC BRCA1 mutation for Slavic population and deserves further investigation.

Download Full-text